National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nivolumab in combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).

 

NCPE Assessment Process Complete
Rapid review commissioned 28/11/2018
Rapid review completed 11/12/2018
Rapid Review outcome Full pharmacoeconomic assessment is recommended